Crawford Healthcare has signed a long-term partnership agreement with Exciton Technologies, a Canadian technology company, to exclusively licence their patented Exsalt® antimicrobial woundcare technology.
Knutsford-based Crawford Healthcare will take over the existing Exciton operations in the US, including its salesforce, to complement Crawford’s own recently opened US entity. The healthcare supplier has also secured the initial rights for most of Europe, Russia and CIS along with other territories, with the option to gain worldwide rights.
As part of the agreement, Crawford Healthcare has taken over the sales and marketing of two existing products marketed in the US. Exsalt® SD7 and T7 are advanced wound dressings which contain the patented silver oxysalts technology providing absorbent (SD7), conformable (T7), and comfortable safe silver dressings with advanced biocidal activity. The technology can also be used as part of other wound dressings.
Richard Anderson, CEO of Crawford Healthcare, said: “The agreement with Exciton further expands the Crawford Healthcare portfolio. The Exsalt® products are perfect additions to our current operation and give us further scope to operate in the burns category. We plan to extend the use of this technology in the Woundcare Category.
“Crawford has taken steps to enter the US market with a number of products in Woundcare and Pressure Relief. This agreement with Exciton will allow us to accelerate our plans in the US and build a much larger salesforce presence.
“Our UK sales are growing strongly and our International expansion is gaining momentum with between 10-14 new territories opening up in 2013.”
Rod Precht, President and Founder of Exciton Technologies, commented: “Partnering with Crawford made sense as the market conditions are ideal to partner with a strong and growing global company who can help take our products to the next level. This arrangement allows Exciton to focus on the development of new products based on its technology platform and increase manufacturing efficiencies to maintain the competitive advantage we have created.”
Crawford Healthcare has more than 15 years experience in supplying specialist dermatology and woundcare products to the NHS including KerraMax Care, KerraPro, the QV Skincare range and the SunSense protection range. This deal is the 10th acquisition or licencing deal Crawford has done since 2011.